← Evidence map

ArticleFrontiers in immunology2026

Real-world safety of first-line enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: evidence from VigiBase and FAERS.

Zuan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Real-world safety of first-line enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: evidence from VigiBase and FAERS. | OpenQuestion